ARCT

NASDAQ 已收盘

Arcturus Therapeutics Holdings Inc.

6.22 USD
+0.24+3.67%
盘后 5.95 -0.83%
2026-08-03
市值
$176.79M
市盈率
EPS
-2.84
股息率
52 周区间
5.50 – 24.17
成交量
612.02K
Beta
2.36
目标价
20.60
52W 低 5.5052W 高 24.17
价格走势

公司简介

Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In additi...